Detalhe da pesquisa
1.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Blood
; 2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551807
2.
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.
Am J Hematol
; 98(8): 1196-1203, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183966
3.
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission.
Am J Hematol
; 97(11): E408-E411, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054774
4.
Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.
Am J Hematol
; 97(12): 1560-1567, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087091
5.
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
Acta Haematol
; 145(5): 529-536, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35717939
6.
Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab.
Am J Hematol
; 97(6): E201-E204, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35266566
7.
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
J Clin Oncol
; 42(13): 1499-1508, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38277619
8.
Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study.
JACC CardioOncol
; 6(1): 71-79, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38510282
9.
Liquid biopsies and minimal residual disease in lymphoid malignancies.
Front Oncol
; 13: 1173701, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37228488
10.
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Lancet Haematol
; 10(1): e24-e34, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36402146
11.
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
J Hematol Oncol
; 16(1): 73, 2023 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37422688
12.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
medRxiv
; 2023 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38106221
13.
Hyperleukocytosis and leukostasis in acute and chronic leukemias.
Leuk Lymphoma
; 63(8): 1780-1791, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35357988
14.
Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors.
Curr Probl Cancer
; 46(3): 100859, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378469
15.
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
Lancet Haematol
; 9(12): e878-e885, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36279879
16.
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
J Hematol Oncol
; 15(1): 12, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35093134
17.
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.
Leuk Lymphoma
; 63(9): 2161-2170, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35442137
18.
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.
Blood Adv
; 6(13): 4006-4014, 2022 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35533262